Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants provide signed written informed consent prior to perform any study-related activity~* Participants has completed the long-term extension of the reSURFACE 2 study~Exclusion Criteria:~* Participants unable to comply with the requirements of the study~* Participants who in the opinion of the investigator should not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tildrakizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).